Amongst the B-ALL patients the presence of CD10 marker was additionally evaluated, analysis revealed no significant differences in the RUNX1 mRNA level between CD10-positive and CD10-negative trials (p = 0.987). This evidence concerns the gene RUNX1 and acute lymphoblastic leukemia.